Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

“Hormone Holiday” Can Improve QoL for Select Patients With Prostate Cancer

February 1st 2016

Leonard G. Gomella, MD, discusses intermittent hormonal therapy for patients with prostate cancer as well as its benefits and challenges.

Genomic Classifier Refines Risk Calculation After Prostatectomy

February 1st 2016

Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.

FDA Grants Olaparib Breakthrough Designation in mCRPC

January 28th 2016

Olaparib (Lynparza) has received an FDA breakthrough therapy designation as a treatment for patients with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in those who have received a prior taxane-based chemotherapy and at least either hormonal agent enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Morris on Mechanism of Action for Radium-223

January 27th 2016

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

Up to 12 Doses of Radium-223 Proven Safe in Bone-Metastatic Prostate Cancer

January 27th 2016

Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was determined to be safe in patients with bone-metastatic castration-resistant prostate cancer.

Radium-223 Benefits Survival, Not Just for Palliative Care

January 25th 2016

Phillip J. Koo, MD, discusses the benefits of radium-223 and why he thinks it is time the use of the drug becomes more widespread for the treatment of mCRPC, and potentially other cancers.

Radiation/Immunotherapy Combos Slow to Gain Traction, But Have Potential in Prostate Cancer

January 20th 2016

Steven Finkelstein, MD, explains why radiation and immunotherapy may be an effective combination in prostate cancer.

Dr. Marshall on ASCENDE-RT Trial for Prostate Cancer

January 13th 2016

David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.

Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

January 11th 2016

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

Hypofractionated Radiotherapy May Be New Standard of Care in Prostate Cancer

January 9th 2016

Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.

Combo of Celecoxib and Zoledronic Acid Improves Survival in Metastatic Prostate Cancer

January 9th 2016

Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.

Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers

January 9th 2016

Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.

Docetaxel First Choice After Abiraterone in 50% of Patients with mCRPC

January 8th 2016

A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer.

Prevalence of DNA Repair Defects Key to Efficacy of PARP Inhibitors in Prostate Cancer

January 6th 2016

Clinical studies suggest that PARP inhibitors are highly efficacious in patients with metastatic castration-resistant prostate cancer with these alternations in DNA repair genes.

Can Aspirin Avert Lethal Prostate Cancer? Long-term Study Suggests a Possible Role

January 4th 2016

Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.

Liquid Biopsy Paves Way for Personalized Selection Tool in Prostate Cancer

January 4th 2016

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

January 3rd 2016

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

FDA Approves Alcohol-Free Docetaxel Formulation

December 28th 2015

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

New Post at MSK Offers Kantoff Another Platform for Leadership in GU Field

December 27th 2015

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Dr. Ciezki on Common Advanced Disease Sites in Patients

December 24th 2015

Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

NEXT PAGE
PREVIOUS PAGE